Sarepta Therapeutics Inc. (SRPT) Rating Reiterated by WBB Securities
Sarepta Therapeutics Inc. (NASDAQ:SRPT)‘s stock had its “strong-buy” rating reissued by investment analysts at WBB Securities in a note issued to investors on Tuesday. They currently have a $60.00 target price on the stock, up from their previous target price of $40.00. WBB Securities’ target price points to a potential upside of 22.60% from the stock’s previous close.
Several other research analysts have also recently weighed in on SRPT. Royal Bank Of Canada restated a “hold” rating and issued a $5.00 price objective on shares of Sarepta Therapeutics in a research report on Friday, June 3rd. Vetr raised Sarepta Therapeutics from a “strong sell” rating to a “buy” rating and set a $17.28 price target for the company in a research note on Thursday, June 2nd. RBC Capital Markets raised Sarepta Therapeutics from a “sector perform” rating to an “outperform” rating in a research note on Monday. William Blair reaffirmed a “market perform” rating on shares of Sarepta Therapeutics in a research note on Monday, June 27th. Finally, Needham & Company LLC raised their price target on Sarepta Therapeutics from $20.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, July 22nd. Two research analysts have rated the stock with a sell rating, four have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $51.01.
Sarepta Therapeutics (NASDAQ:SRPT) traded up 13.87% during trading on Tuesday, reaching $55.73. 21,029,488 shares of the company were exchanged. The stock’s market capitalization is $2.67 billion. Sarepta Therapeutics has a one year low of $8.00 and a one year high of $56.80. The firm’s 50 day moving average price is $27.32 and its 200-day moving average price is $21.07.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/sarepta-therapeutics-inc-srpt-rating-reiterated-by-wbb-securities.html
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.19) by $0.16. During the same quarter last year, the company posted ($0.87) EPS. On average, equities research analysts predict that Sarepta Therapeutics will post ($5.16) earnings per share for the current year.
In other news, CEO Edward M. Md Kaye sold 24,557 shares of the company’s stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $30.00, for a total transaction of $736,710.00. Following the sale, the chief executive officer now directly owns 76,983 shares of the company’s stock, valued at approximately $2,309,490. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 10.90% of the company’s stock.
Several hedge funds have recently modified their holdings of SRPT. Vanguard Group Inc. boosted its stake in shares of Sarepta Therapeutics by 5.5% in the second quarter. Vanguard Group Inc. now owns 3,105,816 shares of the company’s stock valued at $59,227,000 after buying an additional 161,790 shares during the period. State Street Corp increased its position in Sarepta Therapeutics by 25.3% in the second quarter. State Street Corp now owns 3,092,427 shares of the company’s stock valued at $58,976,000 after buying an additional 625,051 shares in the last quarter. BlackRock Fund Advisors increased its position in Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock valued at $32,439,000 after buying an additional 36,371 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its position in Sarepta Therapeutics by 2.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,068,913 shares of the company’s stock valued at $20,865,000 after buying an additional 25,799 shares in the last quarter. Finally, Franklin Resources Inc. bought a new position in Sarepta Therapeutics during the first quarter valued at $13,506,000. 72.09% of the stock is currently owned by institutional investors and hedge funds.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.